B., Skreb, F., Cepelak, I., Romic, Z., & Mayer, L
Evaluation of Decursin and its isomer Decursinol Angelate as potential inhibitors of human glutamate dehydrogenase activity through in Silico and enzymatic assay screening
Keep exfoliating acids and benzoyl peroxide on separate nights so the skin does not get overwhelmed
[3] Evans M, Lewis ED, Zakaria N, Pelipyagina T, Guthrie N
Key medications that slow CKD progression: ACE inhibitors & ARBs cornerstone therapy to reduce proteinuria and protect kidney function SGLT2 inhibitors originally for diabetes, now proven to reduce CKD progression and hospitalizations for heart failure GLP-1 receptor agonists improve glycemic control and show cardiovascular and kidney benefits Non-steroidal MRAs (finerenone) a new option to reduce albuminuria and improve outcomes in diabetic CKD These therapies, when used together and tailored to the patient, represent a modern stack of treatments that can delay or even prevent kidney failure
For short-half-life peptides that fail the oral feasibility test, long-acting injectable formulations may be the most realistic pathway to reduced treatment burden (Table 4)
